MedTrace Logo

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

NCT00614406 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2012-12-13

Study results available
· View outcomes & findings →

Summary

The investigators propose to test the hypothesis that the use of a prostaglandin inhibitor will result in premature luteolysis (ovulation failure) in women.

Conditions

  • Ovulation (Follicular Rupture Yes/no)
  • Menstrual Cycles (Total Length, Bleeding Days)
  • Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)

Interventions

DRUG

Celebrex

One 400mg tablet daily.

DRUG

Placebo

One tablet daily.

Sponsors & Collaborators

Principal Investigators

  • Alison Edelman, MD, MPH · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614406 on ClinicalTrials.gov